BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35075616)

  • 21. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
    Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
    J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circ_0109291 Promotes Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase
    Gao F; Han J; Wang Y; Jia L; Luo W; Zeng Y
    Cancer Biother Radiopharm; 2022 May; 37(4):233-245. PubMed ID: 32758011
    [No Abstract]   [Full Text] [Related]  

  • 24. Circ-SNAP47 (hsa_circ_0016760) and miR-625-5p are regulators of WEE1 in regulation of chemoresistance, growth and invasion of DDP-tolerant NSCLC cells via ceRNA pathway.
    Zou C; Rong F; Zeng Y; Zeng J; Wei R; Wei D
    Environ Toxicol; 2022 Feb; 37(2):224-236. PubMed ID: 34664776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circular RNA hsa_circ_0068252 Functions in Cisplatin Resistance and Immune Response via miR-1304-5p/PD-L1 Axis in Non-Small Cell Lung Cancer.
    Li J; Xu J; Wu G; Ren Y; Wang X; Zhang Q
    Chemotherapy; 2022; 67(4):223-233. PubMed ID: 35649347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circular RNA circ_ASAP2 regulates drug sensitivity and functional behaviors of cisplatin-resistant gastric cancer cells by the miR-330-3p/NT5E axis.
    Sun Y; Ma J; Lin J; Sun D; Song P; Shi L; Li H; Wang R; Wang Z; Liu S
    Anticancer Drugs; 2021 Oct; 32(9):950-961. PubMed ID: 34016832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linc00852 from cisplatin-resistant gastric cancer cell-derived exosomes regulates COMMD7 to promote cisplatin resistance of recipient cells through microRNA-514a-5p.
    Cao S; Fu B; Cai J; Zhang D; Wang C; Wu H
    Cell Biol Toxicol; 2023 Apr; 39(2):483-496. PubMed ID: 35088190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
    Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
    J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
    Wei L; He W; Zhao H; Zhao P
    Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
    Zang H; Li Y; Zhang X; Huang G
    Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer.
    Liu L; Zhang Q; Peng H
    J Chemother; 2023 Feb; 35(1):39-52. PubMed ID: 35289739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.
    Chen H; Li F; Xue Q
    Bioengineered; 2022 Feb; 13(2):2828-2840. PubMed ID: 35068326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway.
    Xu X; Tao R; Sun L; Ji X
    Cancer Cell Int; 2020 Nov; 20(1):552. PubMed ID: 33292236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circ_0067997 boosted the growth while repressed the apoptosis of SGC-7901/DDP cells via repressing miR-615-5p/AKT1 pathway.
    Jiao Y; Fu Y; Gong Y; Wang G; Chen S; Cai G; Wu S; Tang L
    Cancer Biomark; 2023; 37(1):27-38. PubMed ID: 37005876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047.
    Guo J; Chen M; Ai G; Mao W; Li H; Zhou J
    Biomed Pharmacother; 2019 Jul; 115():108957. PubMed ID: 31082770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
    Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.